Molecular Innovations in Urological Cancers: Diagnostics, Prognostics and Precision Therapy
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Urology & Nephrology".
Deadline for manuscript submissions: 30 October 2026 | Viewed by 142
Editors
Interests: urology; genetics; oncology; prostate cancer; liquid biopsy; biomarkers
Interests: cancer risk; cancer progression; cancer; genetics; mutations
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Urological cancers, including prostate cancer, bladder cancer, and renal cell carcinoma, represent a significant global health burden and remain among the most frequently diagnosed malignancies worldwide. Despite considerable advances in surgical techniques, systemic therapies, and imaging modalities, challenges remain in early diagnosis, accurate prognostic stratification, and the selection of optimal therapeutic strategies for individual patients.
Recent developments in molecular biology, genomics, and translational oncology have significantly improved our understanding of the molecular mechanisms underlying the initiation and progression of urological malignancies. These advances have enabled the identification of novel biomarkers and molecular signatures that can support early detection, risk assessment, and personalized treatment strategies. Precision medicine approaches, integrating molecular diagnostics with clinical and pathological data, are increasingly shaping the future of urological oncology.
Molecular biomarkers such as circulating tumor DNA (ctDNA), microRNAs, long non-coding RNAs, exosomes, and gene expression profiles are emerging as promising tools for non-invasive diagnostics and real-time monitoring of disease progression and treatment response. Additionally, advances in next-generation sequencing, multi-omics technologies, and bioinformatics are opening new opportunities for identifying prognostic and predictive markers that may guide targeted therapies and immunotherapeutic strategies.
Targeted therapies and immune checkpoint inhibitors have already transformed the treatment landscape for several urological cancers. However, identifying the patients most likely to benefit from these therapies remains a major challenge. Molecular profiling and biomarker-driven approaches are therefore becoming essential components of modern clinical decision-making in oncology.
This Special Issue aims to provide a comprehensive overview of recent advances in molecular diagnostics, prognostic biomarkers, and precision medicine approaches in urological cancers. We welcome original research articles and reviews addressing molecular mechanisms, biomarker discovery, translational research, and innovative diagnostic and therapeutic strategies.
Topics of interest include, but are not limited to:
- Molecular biomarkers in prostate, bladder, and kidney cancers
- Liquid biopsy and non-invasive diagnostic approaches
- Genomic and transcriptomic profiling in urological oncology
- Prognostic and predictive biomarkers
- Targeted therapies and molecularly guided treatment strategies
- Multi-omics approaches and bioinformatics in cancer research
- Molecular mechanisms of tumor progression and therapy resistance
- Translational research bridging laboratory discoveries and clinical practice
Through this Special Issue, we aim to highlight cutting-edge research and promote interdisciplinary collaboration to advance the field of molecular urological oncology and improve patient outcomes.
Dr. Milena Matuszczak
Prof. Dr. Jan Lubinski
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- molecular biomarkers
- urological cancers
- precision medicine
- molecular diagnostics
- liquid biopsy
- prognostic biomarkers
- targeted therapy
- multi-omics
- prostate cancer
- bladder cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
